[go: up one dir, main page]

MX2018011133A - Composicion farmaceutica para el tratamiento y/o prevencion de cancer. - Google Patents

Composicion farmaceutica para el tratamiento y/o prevencion de cancer.

Info

Publication number
MX2018011133A
MX2018011133A MX2018011133A MX2018011133A MX2018011133A MX 2018011133 A MX2018011133 A MX 2018011133A MX 2018011133 A MX2018011133 A MX 2018011133A MX 2018011133 A MX2018011133 A MX 2018011133A MX 2018011133 A MX2018011133 A MX 2018011133A
Authority
MX
Mexico
Prior art keywords
treating
pharmaceutical composition
preventing cancer
cancer
antibody
Prior art date
Application number
MX2018011133A
Other languages
English (en)
Inventor
Okano Fumiyoshi
Fujita Takayuki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2018011133A publication Critical patent/MX2018011133A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a identificar una proteína antigénica cancerosa específicamente expresada en la superficie de células cancerosas y proporcionar un uso para un anticuerpo que se dirige a la proteína antigénica cancerosa como un agente para tratar y/o prevenir el cáncer. La presente invención se refiere a una composición farmacéutica y similares para tratar y/o prevenir el cáncer. La composición farmacéutica se caracteriza por comprender lo siguiente como ingredientes activos: una proteína MCEMP1 que comprende cualquiera de las secuencias de aminoácidos representadas por un número de secuencias iguales entre las SEQ ID NOS: 2-8 o una secuencia de aminoácido que tiene al menos 80% de identidad de secuencia con estas secuencias de aminoácidos o un fragmento de la proteína MCEMP1 que contiene 7 o más aminoácidos continuos; y un anticuerpo que tiene reactividad inmunológica o un fragmento del mismo.
MX2018011133A 2016-03-28 2017-03-27 Composicion farmaceutica para el tratamiento y/o prevencion de cancer. MX2018011133A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016064035 2016-03-28
PCT/JP2017/012239 WO2017170322A1 (ja) 2016-03-28 2017-03-27 癌の治療及び／又は予防用医薬組成物

Publications (1)

Publication Number Publication Date
MX2018011133A true MX2018011133A (es) 2019-01-14

Family

ID=59965522

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011133A MX2018011133A (es) 2016-03-28 2017-03-27 Composicion farmaceutica para el tratamiento y/o prevencion de cancer.

Country Status (11)

Country Link
US (2) US11492410B2 (es)
EP (1) EP3437655A4 (es)
JP (1) JP7037045B2 (es)
KR (1) KR102412803B1 (es)
CN (1) CN109069629B (es)
AU (1) AU2017241413B2 (es)
BR (1) BR112018069332A2 (es)
CA (1) CA3017714A1 (es)
MX (1) MX2018011133A (es)
RU (1) RU2755894C2 (es)
WO (1) WO2017170322A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025182946A1 (ja) * 2024-02-27 2025-09-04 東レ株式会社 肥満細胞が病態を増悪させる疾患の治療及び／又は予防用医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2472111A1 (en) * 2002-01-03 2003-07-17 Tanox, Inc. Human mast cell-expressed membrane proteins
CA2662340C (en) * 2006-09-08 2016-08-02 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
JP2008118915A (ja) * 2006-11-10 2008-05-29 Kazuto Nishio 胃癌高発現遺伝子特定による胃癌診断および創薬への利用
KR101174452B1 (ko) 2009-05-11 2012-08-16 한국생명공학연구원 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝
EP2532365B1 (en) * 2010-02-04 2016-05-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
EP2388336A1 (en) * 2010-05-19 2011-11-23 Signature Diagnostics AG Method and kits for diagnosing colorectal cancer
US9381210B2 (en) * 2013-04-15 2016-07-05 Wisconsin Alumni Research Foundation Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells

Also Published As

Publication number Publication date
KR102412803B1 (ko) 2022-06-24
RU2755894C2 (ru) 2021-09-22
AU2017241413A1 (en) 2018-10-04
JP7037045B2 (ja) 2022-03-16
CA3017714A1 (en) 2017-10-05
AU2017241413B2 (en) 2024-05-30
CN109069629B (zh) 2023-02-24
US20230030982A1 (en) 2023-02-02
KR20180124954A (ko) 2018-11-21
CN109069629A (zh) 2018-12-21
RU2018137817A3 (es) 2020-08-11
US11492410B2 (en) 2022-11-08
EP3437655A1 (en) 2019-02-06
BR112018069332A2 (pt) 2019-01-22
US20190106505A1 (en) 2019-04-11
RU2018137817A (ru) 2020-04-29
JPWO2017170322A1 (ja) 2019-02-07
EP3437655A4 (en) 2019-11-13
WO2017170322A1 (ja) 2017-10-05

Similar Documents

Publication Publication Date Title
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360208B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX363136B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX360211B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX357505B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2014001371A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2014001372A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico.
MX348577B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
BR112013008407A2 (pt) antígenos de clostridium difficile
WO2016145234A3 (en) Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
WO2015107363A3 (en) Mycobacterial antigen composition
BR112017018703A2 (pt) peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno
AR095076A1 (es) Péptidos y composiciones para el tratamiento de daño articular
MY187334A (en) Xylanase
MX380750B (es) Composición farmacéutica para tratar y/o prevenir el cáncer.
MX2018011133A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2018011109A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
BR112022006862A2 (pt) Peptídeo, composição, e, método para tratar dor ou aumentar a sensibilidade à dor
MY182816A (en) Cancer antigen peptide